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Stlmmsr~ 
Human immunodeficiency virus (HIV) infection of  brain macrophages and astroglial proliferation 
are central features of HIV-induced central nervous system (CNS) disorders. These observations 
suggest that glial cellular interactions participate in disease. In an experimental system to examine 
this process, we found that cocultures of HIV-infected monocytes and astroglia release high levels 
of  cytokines  and  arachidonate  metabolites  leading  to  neuronotoxicity.  HIV-l^D^-infected 
monocytes cocultured with human glia (astrocytoma, neuroglia, and primary human astrocytes) 
synthesized tumor necrosis factor (TNF-o  0 and interleukin 1B (IblB) as assayed  by coupled reverse 
transcription-polymerase  chain reaction,  enzyme-linked immunosorbent assay, and biological 
activity.  The cytokine induction was selective, cell specific, and associated with induction of 
arachidonic acid metabolites.  TNF-B, Iblc~, IL-6, interferon c~ (IFN-c~), and IFN-'y were not 
produced. Leukotriene B4, leukotriene D4, lipoxin A4, and platelet-activating factor were detected 
in large amounts after high-performance liquid chromatography separation and correlated with 
cytokine activity. Specific inhibitors of the arachidonic cascade markedly diminished the cytokine 
response suggesting regulatory relationships between these factors. Cocultures of HIV-infected 
monocytes and neuroblastoma  or endothelial  cells, or HIV-infected  monocyte fluids, sucrose 
gradient-concentrated viral particles, and paraformaldehyde-fixed or freeze-thawed HIV-infected 
monocytes placed onto astroglia failed to induce cytokines and neuronotoxins. This demonstrated 
that viable monocyte-astroglia  interactions  were required for the cell reactions.  The addition 
of actinomycin D  or cycloheximide to the HIV-infected monocytes before coculture reduced, 
>2.5-fold,  the levels of TNF-o~. These results, taken together, suggest that the neuronotoxicity 
associated with HIV central nervous system disorders is mediated, in part, through cytokines 
and arachidonic acid metabolites, produced during cell-to-cell interactions between HIV-infected 
brain macrophages  and astrocytes. 
T 
he central nervous system (CNS) 1 is a major reservoir 
for HIV (1-5), and virus is expressed almost exclusively 
in cells of macrophage lineage (brain macrophages, microglia, 
1 Abbreviations used in this paper: CNS, central nervous system; GAPDH, 
glyceraldehyde 3-phosphate dehydrogenase; MOI, multiplicity  of infection; 
NSE, neuron-specific  enolase;  RT, reverse transcriptase. 
and multinudeated giant cells) (6-10). Productive HIV repli- 
cation in brain macrophages and microglia often predict new 
rological disease (4, 5). In affected tissue up to 15% of brain 
macrophages express HIV gene products (6-10).  Neverthe- 
less, the roh of these HIV-infected cells in disease pathogen- 
esis remains poorly understood. 
Several studies demonstrate entry of virus into the CNS 
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reaction or during subclinical  infection (11-15). However, ex- 
actly how HIV enters the brain and preferentially infects mac- 
rophages are areas of intense debate. Virus-infected brain mac- 
rophages may originate from an expansion of latently infected 
monocytes that carry HIV into the brain (the "Trojan horse" 
hypothesis) and later produce virus (16). Alternatively, virus 
may penetrate the brain through a disrupted blood-brain barrier 
by infected T cells or as free viral particles. In either case the 
results  are identical:  selective productive infection of brain 
macrophages  and microglia.  Whether these HIV-infected brain 
macrophages  induce  disease  through  metabolic,  immune, 
and/or  viral-induced  mechanisms  is critical  to  our  under- 
standing  of HIV neuropathogenesis (17). These issues are made 
ever more apparent  as several reports suggest that low-level 
infection of neurons and glia can produce neurological im- 
pairment  during  HIV infection  (18-20).  The ultimate  ap- 
proaches to therapy would vary dependent upon discovered 
pathogenic mechanisms  for CNS injury. 
Proposed theories of CNS dysfunction abound. These in- 
clude: coexistence of opportunistic CNS infections (21, 22), 
secretory  toxic  factors  from  infected  monocytes,  gpl20- 
mediated neuronal growth factor blockade or killing,  and neu- 
rotoxicity by HIV tat or other viral regulatory components. 
All or any of these mechanisms may result in cytotoxic effects 
in neurons and/or  oligodendrocytes (23-25).  For example, 
gpl20 may antagonize normal vasoactive intestinal  peptide 
(VIP-ergic)  function  in  brain  (23)  or be directly  toxic  to 
neurons.  Studies show that  gpl20 can induce neuronotox- 
icity by increasing free Ca  2+ levels in cultured neurons and 
is prevented by Ca  z+  channel  antagonists  (24). 
Recent reports suggest that brain dysfunction may be related 
to cell-encoded toxins generated from virus-infected macro- 
phages (26, 27). Secretory products from HIV-infected cells 
may alter neuronal viability, damage myelin, or stimulate neu- 
rotransmitters resulting in neuronal dysfunction. Indeed, mac- 
rophages play important  roles in steady-state immune  and 
tissue function.  The regulatory role of macrophages occurs 
through  the release  of numerous secretory molecules made 
under a variety of physiologic conditions.  Changes in the secre- 
tion or release of certain of these mediators may lead to dis- 
ease. In support of this idea are recent studies demonstrating 
that disordered secretion of one or more cellular factors from 
HIV-infected macrophages produces neuronal death in vitro 
(26, 27). In one report, HIV-infected U937 cells, a myelomono- 
cytic cell line,  released toxic factors that destroyed cultured 
chick  and  rat  neurons  (27).  The monocyte-produced neu- 
rotoxin(s) were heat stable and protease resistant,  and acted 
by way of N-methyl-o-aspartate  (NMDA)  receptors.  The 
studies suggested that HIV-infected macrophages and microglia 
in brain continuously disrupt neurologic function leading to 
cognitive CNS dysfunction. However, two recent reports failed 
to confirm these observations (28, 29). One study (29) demon- 
strated neurotoxicity only after cell-to-cell contact between 
HIV-infected monocytic and human neural cells. In this and 
a study from our own laboratory (28) investigators  found 
no morphological alterations of neurons exposed to HIVol- 
infected monocyte fluids.  Thus,  if the macrophage  plays  a 
role in virus-induced neuropathology it may act through cell- 
to-cell interactions  with neurons and glia to produce CNS 
tissue damage  (29).  Perhaps  this  occurs  through  cytokine 
and/or other neuronotoxic factor release during cell-to-cell 
contact. Indeed, similar mechanisms are operative for cytokine 
induction in peripheral  blood. For example, IFN-oe is induced 
during cell-to-ceU interactions  with HIV-infected  macrophages 
and PBMC (30). Similarly,  neuronotoxins could be produced 
from glia during cell-to-cell interactions with infected brain 
macrophages. To investigate this possibility we recovered cul- 
ture fluids from cell mixtures of virus-infected monocytes and 
astroglia.  Assay of fluids after cocultivation showed high levels 
of arachidonic acid metabolites, cytokines, and neuronotoxic 
activity. 
Materials and Methods 
Isolation and Culture of  Monocytes and Human Neural Cells.  Mono- 
cytes were recovered from PBMC of HIV and hepatitis B-seronega- 
tive donors after leukapheresis and purified by countercurrent  cen- 
trifugal  elutriation.  Cell suspensions were >98% monocytes by 
criteria  of cell morphology  in  Wright-stained  cytosmears, by 
granular peroxidase, and by nonspecific esterase. Monocytes were 
cultured as adherent monolayers (106 cells/ml in 24-mm plastic cul- 
ture wells) in DMEM (Sigma Chemical Co., St. Louis, MO) with 
10% heat-inactivated AB § human serum, 50/,g/ml gentamicin, 
and 1,000 U/ml highly purified (<0.01 ng/ml endotoxin) recom- 
binant  human  macrophage  MCSF  (FAP-809;  Cetus  Corp., 
Emeryville, CA) (31). 
Human brain tumor-derived  cell lines were obtained from the 
following sources: U251 MG from D. Bigner (32), U373 MG from 
B. Westermark (33), and SK-N-MC (34) and H4 (HTB 148) (35) 
from the from American Type Culture Collection (ATCC; Rock- 
ville, MD). The cells were grown as adherent monolayers in DMEM 
(Sigma Chemical Co.) with 10% heat-inactivated FCS and 50/zg/ml 
gentamicin. Human endothelial cells were a gift from P. I. Lelkes 
(36). Cell lines were fully characterized to their cell origins (37, 
38). Primary human astrocytes were prepared from second-trimester 
human fetal brain tissue obtained from elective abortions (performed 
in full compliance with both National  Institutes  of Health  and 
University of Rochester guidelines). Brain tissue composed of telen- 
cephalon with both cortical and ventricular surfaces was dissected 
in cold HBSS with Hepes and 50/zg/ml gentamicin,  then trans- 
ferred to 20 ml ice-cold (4~  DMEM/F12 (Gibco Laboratories, 
Grand Island, NY) with 10% heat-inactivated FCS. The tissue was 
mechanically dissociated by teasing through a Nitex bag with a 
glass pestle. Cells were resuspended in media and filtered through 
a 230- and then 140-~m sieve. The cell suspension was centrifuged, 
washed twice in media, then plated in DMEM containing  10% 
FCS and 50/zg/ml gentamicin  into  75-cm  2 tissue culture  flasks 
(Coming,  Coming,  NY) at a cell density of 2  x  10  s cells/ml. 
Media  was  exchanged every 3  d.  Nonadherent  microglia  and 
oligodendrocytes were removed by gentle  agitation  and circular 
shaking of cultured cell preparations 10 d after plating. The purity 
of the astrocyte cultures was ~95% by immunostaining  for glial 
fibrillary acidic protein  (GFAP) (39). Cells were cultured  as ad- 
herent monolayers in DMEM (Sigma Chemical Co.) with 10% 
heat-inactivated FCS (Sterile Systems, Inc., Logan, UT), 20/*g/ml 
gentamicin, and 1% glutamine. All culture reagents were screened 
and found negative for endotoxin  contamination. 
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7 d were exposed at a multiplicity of infection (MOI) of 0.01 infec- 
tious virus/target cell to ADA, or 24 monocyte tropic HIV-1 strains 
(40).  All viral  stocks  were tested and found free of mycoplasma 
contamination (Gen-probe II; Gen-probe Inc., San Diego, CA). 
Culture medium was half-exchanged every 2-3 d.  Reverse tran- 
scriptase (RT) activity was determined in replicate samples of cul- 
ture fluids added to a reaction mixture of 0.05% NP-40 (Sigma 
Chemical Co.),  10/~g/ml poly(A), 0.25 U/ml oligo(dT) (Phar- 
macia Fine Chemicals, Piscataway, NJ), 5 mM dithiothreitol (Phar- 
macia Fine Chemicals),  150 mM KC1, 15 mM MgCI~,  and ~H- 
dTTP (2 Ci/mmol; Amersham Corp., Arlington Heights, IL) in 
pH 7.9 Tris-HC1 buffer for 24 h at 37~  Radiolabeled nucleotides 
were precipitated with cold 10% TCA and washed with 10% TCA 
and 95% ethanol in an automatic cell harvester (Skatron Inc., Ster- 
ling, VA) on glass filter discs. Radioactivity was estimated by liquid 
scintillation spectroscopy (41). 
Chemical Reagents.  Dexamethasone was purchased from Sigma 
Chemical Co.  and indomethacin and  nordihydroguaiaretic acid 
(NDGA) from Cayman Chemical Co.,  Ann Arbor, MI. All re- 
agents were dissolved in ethanol and diluted with complete macro- 
phage  media.  Final  ethanol  concentration  in  cell  cultures  was 
~<0.1%. 
Quantitations of Cytokine Activity.  Culture fluids from control 
and HIV-infected monocytes were analyzed by ELISA for the human 
cytokines TNF-~, IL-I~, IL-1/~, and IL-6 (Quantikine Immuno- 
assay; Research and Diagnostics Systems, Minneapolis, MN). IFN 
activity in culture fluids was assayed by inhibition of cytopathic 
effects induced by vesicular stomatitis virus (VSV) in MDBK cells 
(42). TNF bioactivity was performed according to standard proce- 
dures (43).  Briefly, the routine L929 cell line was propagated in 
DMEM (Sigma Chemical Co.), 5% FCS,  1% glutamine, and 20 
~tg/ml  gentamicin. Cells  were retrieved in log phase  and placed 
(0.5  ￿  105/well) in 96-well plates  (Costar) with actinomycin D. 
Culture fluids were inoculated into cell monolayers, and degree of 
cell lysis was determined by crystal violet staining after a 24-h in- 
cubation. 
Coupled RT-PCR Detection of Cytokine and HIVspecific RNA.  Lev- 
els  of cytokine KNAs  were estimated after KT with  antisense 
primers  and PCK amplification of the cDNA  transcripts.  The 
mKNA for the cellular enzyme, glyceraldehyde  3-phosphate de- 
hydrogenase (GAPDH), served as an internal control to allow anal- 
ysis and comparison of KNA species between different samples. 
Briefly, 2.0/~g total cellular KNA in 0.025 ml was mixed with 
0.3 #g of  the antisense primers for GAPDH, TNF-c~, TNF-~/, IL-lc~, 
Ibl/~, II.-6, IFN-c~, IFN-% and IFN-/~ (44). Table 1 lists the primer 
sequences used in these studies.  The mixture was heated at 70~ 
for 5 rain, cooled on ice, and treated with 500 U of Moloney mu- 
fine leukemia virus KT (Bethesda Research Laboratories, Bethesda, 
MD) and 0.5 mM each of all four deoxynucleotide triphosphates. 
ILT reactions were at 37~  for 15 rain, then stopped by heating 
at 95~  for 10 rain. For PCK amplification of the cDNA prod- 
ucts, reaction mixtures were divided into equal aliquots and mixed 
with 0.5 #g sense and antisense primers, 0.5 mM deoxynucleotide 
triphosphates, and 2 U Amplitaq (Cetus Corp., Emeryville, CA). 
The products of 25 cycles (1.5 rain,  94~  1.5 rain,  50~  and 
2.0 min, 72~  were analyzed by Southern blot hybridization. The 
oligo-nucleotides were synthesized on DNA synthesizer (Applied 
Biosystems, Inc., Foster, City, CA) and checked for purity by poly- 
nucleotide kinase labeling and sequence gel analysis. Oligonucleo- 
tides  were typically 95%  pure. 
Fetal Rat  and Human Brain Cortical Explant Cultures.  Fetal 
Sprague-Dawley rat (15-d gestational age) forebrains were dissociated 
by tituration into a single cell suspension and adjusted to 106 viable 
cells/ml. Cells were plated in poly4-1ysine-treated plastic  culture 
wells in a 1:1 mixture of Eagle and Ham's F12K medium with 50 
U/ml penicillin,  50 #g/ml streptomycin, 600/~g/ml glucose, 10% 
horse serum, and 10% FCS (45). Alternatively, ceils were plated 
into N5 medium supplemented with 5% horse serum fraction (46). 
After 5 d, cultures were treated with 10 #M cytosine arabinoside 
(Ara-C) (Sigma  Chemical Co.) for 48 h  to deplete proliferating 
astrocytes,  fibroblasts,  and microglial cells (29). The composition 
of these Ara-C-treated cultures at day 10 was 70-85% neurons by 
neuron-specific enolase  (NSE;  Dako  Corp.,  Carpinteria,  CA), 
10-15% microglia by latex-bead phagocytosis and rat OX-6 staining, 
and <5-10% astrocytes by morphology and glial fibrillary acidic 
protein (GFAP; Dako Corp.) staining. Cells were treated with con- 
ditioned media from cell cultures for 1-7 d and analyzed for neu- 
ronotoxicity. 
Quantitations of Neuronal Cell Growth and Survival.  The meta- 
bolic activity and number of viable cells/culture were assessed by 
conversion of 3-(4,5-dimethylthiazol-2yl)-2,5-diphenyl tetrazolium 
(MTT) bromide, and color intensity was measured at OD490 om 
(47, 48).  Cell morphology in neuronal cultures depleted of glial 
cells was examined under phase-contrast microscopy or after fixa- 
tion with 80% methanol and Wright-Giemsa stain. Morphologic 
changes in these neuron-enriched cell cultures correlated directly 
with MTT levels and were scored as 0 (no neuritic outgrowth), 
+  (dendritic outgrowth  2-4 perikaryons distance  in  >/50%  of 
cells/field), or + +  (dendritic outgrowth 4-8 perikaryons distance 
in >~50% of ceils/field).  Generally,  100 cells in four fields/culture 
were examined on successive days. In some studies,  identical mi- 
croscopic  fields were photographed at serial intervals  to decrease 
sampling variability. 
Analysis of FH]Arachidonic Acid Metabolites Released by HIV- 
infected Monocytes and Cocultures of HIV-infected Monocytes and As- 
troglia.  HIV-infected or control uninfected monocytes (5  x  106 
cells/ml) were cultured in 35-ram wells (Costar) in media containing 
10% AB § human sera and [3H]arachidonic  acid (1.0 mCi/ml;  1 
Ci  =  37 GBq; American Radiolabeled Chemicals Inc., St. Louis, 
MO) added to the cultures for 18 h. HPLC procedures followed 
previously published methods (49, 50). A brief description of the 
protocol used in these experiments is outlined below. 
The monocytes were washed three times with DMEM in 1% 
BSA (Sigma  Chemical Co.) then incubated for 20 s to 180 rain 
with or without equal numbers of U251 MG astroglial  cells. The 
reaction was stopped by the addition of 10 #l formic acid and 25 
/zl butylated hydroxytoluene in methanol, and the samples were 
placed on dry ice. Supernatant fluids were removed and the cells 
scraped  after the addition of 500/~1 of HPLC-grade water.  The 
cell lysate was combined with the culture supernatants from each 
well and placed into 10-ml polypropylene centrifuge tubes.  The 
fractured cell-supernatant mixtures were centrifuged at 400 g for 
5 min and the clarified supernatants stored under argon at  -70~ 
in 4-ml dram vials. Before analysis, a 2-ml thawed sample was ad- 
justed to pH 4.0 with 22 M formic acid and microcentrifuged for 
1 rain. The internal standard mix was added to the cell lysate. It 
contained  hydroxyeicosadienoic  acid  (for  spectrophotometric 
verification of elution position accuracy)  and [14C]eicosatrienoic 
acid (for quantitation of sample recovery and inter/intrasample com- 
parisons).  DPMs of each sample were adjusted based on recovered 
[14C]eicostrienoic  acid.  A  C18  Sep-Pak  cartridge  (Waters  As- 
sociates, Milford, MA) was activated  by placing 4 ml of HPLC- 
grade methanol through the cartridge. The C18 Sep-Pak was washed 
with 10 ml of HPLC-grade water.  The sample was applied to the 
C18 Sep-Pack cartridge (Waters Associates) followed by a 2.5-ml 
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with a mixture of  85% acetonitrile and 15% methanol The ehant 
was concentrated and dried with a Speed-Vac  concentrator (Savant 
Instruments,  Inc., Farmingdale, NY).  The arachidonic acid me- 
tabolites were then dissolved  in methanol and transferred to HPLC 
vials (National Scientific  Co., Lawrenceville,  GA) for injection. The 
arachidonic acid metabolites extracted were then injected onto a 
reverse-phase C-18 column  using  an  analytical  HPLC  system 
(Beckman Instruments,  Inc., Palo Alto, CA). Spectraphotometric 
analyses were performed with a UV detector (166; Beckman In- 
struments,  Inc.). l-rain fractions were collected during a 96-rain 
chromatography run, and total DPM was determined in each frac- 
tion. A second separately collected ehtion was performed on the 
Sep-Pak that quantitatively removed  platelet-activating  factor (PAF). 
The eluate was dried and analyzed using a quantitative RIA kit 
(Amersham Corp.,  Arlington Heights,  IL). 
Results 
No Evidence  for Neuronotaxic Activity in Culture Fluids of  HIV- 
infected Monocytes or Glial Cells.  Monocytes and glia (U251 
MG, U373 MG, and H4 HTB 148) cells were infected with 
Table  1.  Nucleotide Primers in Coupled R T-PCR Detection of Cytokines 
Amplification  Nucleotide 
product size  position  Primer  Sequence 
TNF-~ 
237 bp 
TNF-3 
147 bp 
IL-la 
201 bp 
IL-13 
179 bp 
IL-6 
159 bp 
IFN-cr 
274 bp 
IFN-fl 
186 bp 
IFN-  7 
168 bp 
GAPDH 
195 bp 
503-527  Sense 
740-716  Antisense 
588-608  Probe 
238-258 
385-366 
341-360 
435-459 
636-615 
481-501 
480-500 
659-638 
549-567 
317-337 
476-455 
399-420 
240-259 
514-492 
433-454 
343-364 
529-509 
379-400 
372-391 
540-521 
463-482 
199-217 
394-374 
280-299 
Sense 
Antisense 
Probe 
Sense 
Antisense 
Probe 
Sense 
Antisense 
Probe 
Sense 
Antisense 
Probe 
Sense 
Antisense 
Probe 
Sense 
Antisense 
Probe 
Sense 
Antisense 
Probe 
Sense 
Antisense 
Probe 
GAGCTGAGAGATAACCAGCTGGTG 
CAGATAGATGGGCTCATACCAGGG 
CCCTCCACCCATGTGCTCCTC 
AACATGACCCTCCTAGACCA 
TCCCTGGAAGTACCTCCTCA 
GCAATTAGCAGCCCTGCACT 
TTCGAGCCAATGATCAGTACCTCA 
TTTGGGTATCTCAGGCATCTCC 
GATGAAGCAGTGAAATTTGAC 
AAAAGCTTGGTGATGTCTGG 
TTTCAACACGCAGGACAGG 
ATGGAGCAACAAGTGGTG 
GTGTGAAAGCAGCAAAGAGGC 
CTGGAGGTACTCTAGGTATAC 
GGATTCAATGAGGAGACTTGC 
TCCATGAGATGATCCAGCAG 
ATTTCTGCTCTGACAACCTCCC 
AAATACTTCCAAAGAATCACT 
GATTCATCTAGCACTGGCTGG 
CTTCAGGTAATGCAGAATCC 
GAGAACCTCCTGGCTAATGTC 
GCATCCAAAAGAGTGTGGAG 
GACAGTTCAGCCATCACTTGG 
GACTAATTATTCGGTAACTGAC 
CCATGGAGAAGGCTGGGG 
CAAAGTTGTCATGGATGACC 
CTAAGCAGTTGGTGGTGCA 
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infected and control uninfected cells were half-exchanged at 
2-3-d intervals then added, 14 d after plating and 7 d after 
infection, to rat brain explant and/or SK-N-MC human neu- 
roblastoma cells. The composition of fetal rat brain cultures 
at the time of experimental inoculation (day 10 of culture) 
was  70-85%  neurons  (neurofilament and  neuron-specific 
enolase-positive cells), 10-15% microglia (OX-6-positive cells 
that ingest latex beads),  5-10%  astrocytes (GFAP-positive 
cells),  and 0-3%  fibroblasts (vimentin-positive cells  [44]). 
Additions of fluids from HIV-infected and control uninfected 
monocytes to the rat brain explants showed neuronotrophic 
activity.  Numbers  of NSE +  neurons  treated  with  HIV- 
infected and control monocyte fluids for 5 d were two- to 
threefold higher than equal numbers of neurons treated with 
culture medium alone (Table 2 and Fig.  1). Fetal rat brain 
cells inoculated with fluids from HIV-infccted or control unin- 
fected U251 MG, U373 MG, or HTB 148 cells also showed 
no neuronotoxicity (Table 2). 
Fluids  from HIV-infected Monocyte-Glial Cell Interactions Pro- 
duce Neuronotoxic Factors,  The absence of neuronotoxic ac- 
tivity from HIV-infected monocytes or virus-infected neural 
cells led to assay of cell mixtures for neuronotoxic activities. 
Monocytes were infected with HIV-1AD^ for 7 d, harvested 
from teflon flasks, then placed onto equal numbers of neural 
cells. Fluids were harvested at 24 and 48 h after cocultivation 
then placed onto rat brain explant for assay of neuronotox- 
icity. In contrast to previous results, fluids from cocultures 
of HIV-infected monocytes with U251 MG, U373 MG, or 
HTB 148 astroglial cells were profoundly neuronotoxic (Table 
2 and Fig. 1). Within 2 d after fluid addition neurons were 
swollen and vacuolated (Fig.  1). These fluids were also toxic 
for SK-N-MC neuroblastoma cells. The neural cell toxic ac- 
tivity was only produced in mixtures of HIV-infected mono- 
cytes and glia (U251 MG, U373 MG, and HTB 148 cell lines) 
(Table 2). Dose-response analysis of culture fluids from HIV- 
infected monocyte-astroglia (U251  MG) mixtures showed 
significant neuronotoxicity with dilutions of ~1:20 of the 
fluids.  Indeed, a/>50% loss of viable neurons/well was evi- 
dent when a 20-fold dilution of culture fluids of  HIV-infected 
monocytes-astroglia was placed onto rat fetal neurons (Fig. 
2). The toxic effects were cell specific. Fluids obtained from 
mixtures of HIV-infected monocytes and SK-N-MC (neuro- 
blastoma)- or HIV-infected monocytes and endothelial cells 
showed no neuronotoxic activity (Table 2). The HIV-infected 
monocytes and U251 glial cells fluids were not toxic for rat 
or human astrocytes and fibroblasts (data not shown). 
Mechanisms for Neuronotoxicity Analysis of Cytokine Gene 
Expression.  A variety of cytokines may produce neurotox- 
icity and as such contribute to the pathogenesis of CNS dis- 
ease. Two cytokines, IblB and TNF-ob,  are associated with 
glial proliferation, neurotoxicity, and demydination. Interest- 
ingly, these cellular effects are all prominent features of HIV- 
related encephalopathy. For example, TNF, at high concen- 
trations,  is  a  neurotoxin  (28,  51,  52).  Human  astrocytes 
proliferate in response to TNF-c~ and IL-1B (53, 54), and con- 
ditioned medium from LPS-treated astrocytes stimulates HIV-1 
gene expression in monocytic cells (55). These observations 
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led us to investigate whether TNF-cr and IL-1B produced the 
neurotoxicity observed in supernatant fluids of HIV-infected 
monocytes and astroglia. 
Initial experiments were performed to determine whether 
the addition of HIV-infected monocytes to astroglia resulted 
Table  2.  Neuron  Survival  and Differentiation in Rat Brain 
Explants Treated with Culture Fluids from Uninfected and 
HIV-l-infected Cells 
Neuronal survival 
Treated with:  and differentiation 
Tissue culture medium 
Medium alone  + 
Medium with MCSF  + 
Monocyte culture fluids 
Control monocytes  + + 
HIV-ls,^-infected monocytes  + + 
HIV and its products 
HIV-1.TLVmB  + 
HIV-I~  + 
HIV-laDA  + 
HIV gp120  + 
HIV-infected monocytes cocultured with: 
Endothelial cells  + 
SK-N-MC (neuroblastoma)  + 
U251 MG (astroglia)  0 
U373 MG (astroglia)  0 
HTB 148 (neuroglia)  0 
U251 MG astroglia cocultured with: 
Uninfected monocytes  + 
HIV-laD^  + 
Freeze-thawed HIV-infected 
monocytes  + 
Paraformaldehyde-fixed HIV-infected 
monocytes  + 
Data show neuron survival and differentiation in fetal rat brain explants 
cultured for 10 d then treated for 5 d with monocytes media, conditioned 
media  containing 20%  (vol/vol) fluids  from  uninfected  monocytes, 
HIV-1AD^ and HIV-l~-infeeted monocytes,  or with HIV-IHXVmB or 
HIV-IAD^ virus stock (>10  s HIV partides/ml by grid count on trans- 
mission electron microscopy), and 500 ng/rnl recombinant HIV-lwrtvlm 
gp120.  Conditioned  media  containing 20%  (vol/vol)  fluids  from 
HIV-l~D^-infected monocytes cocultured with endothelial cells, SK-N- 
MC (neuroblastoma), and U251 glial cells, and U251 MG astroglial cells 
incubated with  HIV-1AD^, freeze-thawed  HIV-infected  monocytes, 
paraforrnaldehyde-fixed HIV-infected monocytes, and uninfected mono- 
cytes were harvested after 24 h and assayed for neuronotoxicity. Neuron 
survival and extent of differentiation was estimated by cell morphology 
on  phase  contrast  microscopy  or  on  methanol-fixed,  Wright- 
Giemsa-stained  slides as outlined in Materials and Methods.  Cell num- 
ber was confirmed by MTT conversion as estimated by spectrophotome- 
try at OD~90, and was scored as: 0, no neuritic outgrowth;  +, dendritic 
outgrowth of 2-4 perikaryons distance in )50% of ceUs/fidd; or + +, 
dendritic outgrowth of 4-8 perikaryons distance in )50% of cells/field. F
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Figure 2.  Correlation between neuronotoxicity and dilution of culture 
fluids from control uninfected monocytes, HIV-infected monocytes, and 
HIV-infected monocyte-astroglia (U251 MG cell) cocuhures. Rat neuronal 
cell cultures at 10 d were exposed to twofold  serial dilutions of culture 
fluids and analyzed for neuronotoxicity  by counting neurons in triplicate 
wells in four microscope fields/well. Neuron survival was estimated by 
cell morphology on phase-contrast microscopy. Error bars represent mean 
_+  SD. 
in cytokine gene expression. We examined the levels  of TNF-ce 
and I1:1fl by coupled RT-PCR in cell cocuhures. The mRNA 
for the constitutive cellular enzyme, GAPDH, was examined 
as the reference cellular transcript. GAPDH mRNA amplifi- 
cation products were present at equivalent levels in all cell 
lysates. IFN-7 mRNA was not detected in any cell lysate 
(data not shown), demonstrating that a mixed T  cell reac- 
tion was not an explanation for any cytokine mRNA expres- 
sion observed.  The mRNAs for I1:1fl, IL-lc~, TNF-o~, and 
TNF-fl in cell lysates of uninfected and HIV-infected mono- 
cyte cultures were absent (Fig. 3, lanes 1 and 2; and Table 
3). However, the predicted 237- and 179-bp amplification prod- 
ucts of TNF-ot and IL-lfl mRNAs were readily seen in cell 
lysates of uninfected and HIV-infected monocytes and glia 
(U251 MG and HTB 148 cell lines) (Fig. 3, lanes 3 and 4, 
and 9 and 10). Interestingly, TNF-oe and IL-13 mRNAs were 
not detected in cell lysate and culture fluids of uninfected con- 
trol or HIV-infected monocytes cocuhured with endothelial 
cells (Fig.  3,  lanes 7 and 8) or neurohlastoma cells (SK-N- 
MC cells) (Fig. 3, lanes 11 and 12). Control uninfected and 
HIV-infected U251 MG cells also showed no TNF-ot and I1:1fl 
mRNAs (Fig. 3, lanes 5 and 6). Replicate experiments with 
primer pairs for three other cytokines (I1:1c~, TNF-fl, or I1:6) 
(data not shown) were below the limits of PCR detection 
(Fig. 3). These results,  taken together, show a selective and 
cell-specific induction of TNF-ce and II:1/3 mRNA during 
the interaction between HIV-infected or control uninfected 
monocytes and glia. 
The high levels  ofmRNAs were not always associated with 
Figure3.  Induction  of cytokine mRNA during HIV-infected  monocyte- 
astrogial cell cocuhivation. Monocytes cultured 7 d as adherent monolayers 
were exposed to HIV at an MOI of 0.01. 7 d after infection HIV-infected 
or control uninfected monocytes were cocultured  1:1 (monocytes/neural 
cells) with several  different cell lines or primary cells for 24 h as outlined 
in Materials and Methods. RNA from cell lysates was extracted and mixed 
with antisense primers. After RT, cDNAs were amplified by PCR and 
the products of 25 cycles analyzed by Southern  blot hybridization  with 
cytokine~specific  probes (see  Table 1). Coupled RT-PCR amplification  prod- 
ucts from cell lysates of monocytes and/or neuronal cells cultured under 
different conditions are pictured in lanes: I, uninfected monocytes; 2, HIV- 
infected monocytes; 3, uninfected monocytes cocuhured with U251 glial 
cells; 4, HIV-infected monocytes cocukured with U251 glial cells; 5, unin- 
fected U251 cell; 6, HIV-mfected  U251 cells; 7, uninfected monocytes cocul- 
tured with endothelial cells; 8, HIV-infected monocytes cocultured with 
endothelial cells; 9, uninfected monocytes cocultured with H4 HTB 148 
cells; 10, HIV-infected monocytes cocultured with H4 HTB148 cells; 1I, 
uninfected monocytes cocultured with SK-N-MC cells; 12, HIV-infected 
monocytes cocuhured with SK-N-MC cells. Lane 13 is the X plasmid con- 
trol, and lane 14 is the PCR reaction run without RT. The latter specified 
that RNA not contaminating  cellular DNA was amplified in the reaction. 
similarly high levels of proteins (Table 3). TNF-ot and I1:lfl 
protein and biological activity were seen only in coculture 
fluids of HIV-l-infected monocytes and glia (Table 3). The 
TNF-oe and I1:1fl proteins were observed during cocuhure 
of HIV-infected monocytes and astroglial (U251 MG). Max- 
imum levels were present 12-48 h after cocuhivation. In a 
series of four replicate experiments maximum levels of TNF-o~ 
were 1,000-9,000 pg/ml (mean of 5,000), while I1:1fl levels 
ranged from 400 to 5,000 pg/ml (mean of 900) (Figs. 4 and 
5). The results were confirmed  by assays of TNF activity (Fig. 
6). The underlying  basis for this 10-fold difference was related 
to the levels of productive HIV infection. Peak cytokine levels 
occurred during the initial rise of RT activity,  3-5 d after 
virus infection, and diminished to baseline by day 10 (data 
not shown). TNF-cr  and I1:1fl proteins were also detected 
at low levels (<100 pg/ml) in cocultures of uninfected mono- 
cytes and astroglia (U251 MG and human astrocytes),  The 
latter results suggest that the interactions seen between HIV- 
infected monocytes  and glia are an extension of a normal phys- 
iological  response.  In all experiments assayed, the cytokine 
response mirrored the neuronotoxic  response (data not shown). 
Analysis of the Cytokine-producing Cell in Monocyte.Astroglia 
Cocultures.  Cytokines produced during the interactions be- 
tween HIV-infected monocytes and glia required viable mix- 
1709  Genis et al. Table  3.  Levels of TNF-cr raRNA and Protein after Coculture 
of HIV-infected Monocytes and the U251 Glial 
Cell Line 
TNF-o~ 
Cell treatments  mRNA  Protein 
Vg/ral 
Monocytes cultured with: 
Medium  0  0 
LPS  + +  2,250 
Medium with MCSF  0  0 
HIV-infected monocytes cultured 
with: 
Medium  0  0 
Endothelial cell  0  0 
SK-N-MC (neuroblastoma)  0  0 
HTB  148  + +  2,140 
U251 glial cells  + +  3,460 
Cycloheximide then U251 MG 
cells  + + +  1,300 
Actinomycin D  then U251 MG 
cells  +/-  90 
U251 MG astroglial cells 
cultured with: 
Uninfected monocytes  + +  50 
HIV-I^D^  0  0 
Freeze-thawed HIV-infected 
monocytes  0  0 
Paraform.-fixed HIV-infected 
monocytes  0  0 
TNF-a mRNA and protein in cell lysates and culture fluids of uninfect- 
ed control, HIV-l~^-infected monocytes, and/or U251 MG astroglial 
cells after 24-h incubations with the treatments listed. Monocytes cul- 
tured 7 d as adherent monolayers were exposed to HIV at a MOI of 
0.01.1 wk after infection virus-infected monocytes were cocultured with 
media or equal numbers of: endothelial cells, SK-N-MC (neuroblasto- 
ma) cells, HTB 148 glial cells, U251  MG astroglial cells, cycloheximide 
then U251  MG astroglial cells, and cydoheximide then U251 astroglial 
cells. The U251 MG astroglial cells were incubated with: uninfected mono- 
cytes, HIV-I^D^, mycoplasma-infected monocytes, and freeze-thawed  or 
par^formaldehyde-fixed  HIV-infected monocytes. Cytokine mKNA lev- 
els were detected by coupled KT-PCK amplifications  from cell lysates. 
The extracted KNAs were mixed with antisense primers and, after KT, 
eDNA was amplified by PCK. The products of 25 cycles were analyzed 
by Southern btot hybridization. KNA was not detected (0), detected at 
low levels (+), was readily detected (+ + ), or detected at high levels 
( +  + + ). Cytokine levels in culture fluids were determined by ELISA. 
tures of both call types. When U251 MG or HTB 148 were 
mixed with 4% par^formaldehyde-fixed  or freeze-thawed HIV- 
infected monocytes, cytokines were not detected (Tables 3). 
Pretreatment of HIV-infected monocytes with cydoheximide 
or actinomycin D  before coculture was used to determine 
if the infected monocytes were primary cytokine producers. 
Cycloheximide and actinomycin D  were titrated to inhibit 
HIV mRNA and protein synthesis (positive controls for this 
assay system) and used at concentrations of 30 and 5/~g/ml, 
respectively. In these assays, cycloheximide- or actinomycin 
D-treated monocytes were washed extensively before addi- 
tion ofU251 MG astroglial cells at equal cell concentrations. 
Analysis of TNF-c~ mRNA levels from cell lysates prepared 
from cycloheximide-  or  actinomycin D-treated cocultures 
showed increased and decreased levels of TNF-c~ mRNA, 
respectively  (Fig.  7).  However, both additions resulted in 
significant reductions in both TNF-c~ and II,1B proteins (Table 
3; and unpublished observations). The higher levels of TNF-a 
protein seen after cycloheximide compared with actinomycin 
D  treatment likely reflect the reversibility of cycloheximide 
after a 24-h wash out. That these inhibitors of RNA and 
protein synthesis  had opposite effects on levels of TNF-ol 
mRNA was not surprising. Indeed, previous reports show 
an upregulation of TNF-c~ mRNA in monocytes after both 
LPS and cycloheximide treatment (56, 57). These results cou- 
pled with the recent demonstration of TNF-c~ and IblB pro- 
tein in HIV-infected brain macrophages (58) support the no- 
tion that the macrophage is the primary cytokine producer. 
Furthermore, reproduction of these experimental findings with 
cocukures of H1V-infected  monocytes and normal human fetal 
astrocytes (data not shown) lends support for the biological 
relevance of the described experimental system. 
The role of TNF-(x and IL-1/3 in the observed neuronotox- 
icity was next explored.  Toxicity  of recombinant human 
(rh)TNF-ol (Amgen Biologicals, Thousand Oaks, CA) and 
rhll.-1/3 (Collaborative Research,  Bedford, MA) was tested 
on rat fetal neuronal cultures as described above. Replicate 
experiments  were  performed  with  recombinant  murine 
(rm)TNF-ol (Genzyme, Boston, MA) and rmlblB (Hoffman- 
La Roche, Inc., Nutley, NJ).  The cytokine concentrations 
used in these assays were extrapolated from data from cocul- 
tures of HIV-infected monocytes and astroglia (1-10 ng/ml 
of recombinant protein). Inoculation of TNF-o~ and IL-I~ 
alone or in combination to fetal neuronal cultures produced 
no neuronotoxicity. Moreover,  mycoplasma and endotoxin 
contaminations were ruled out as the neuronotoxin in the 
cell and viral preparations.  Mycoplasma was not detected by 
hybridization assays in any of 10 randomly selected culture 
fluids. The levels of endotoxin contamination as detected by 
the Limulus amebocyte lysate assay were <50 pg/ml. The ad- 
dition of polymyxin B at 15/~g/ml, a concentration known 
to  inhibit  the LPS-induced cytokine production,  had no 
significant effect on cytokine levels observed in HIV-infected 
monocyte-astroglia cocultures. These results, taken together, 
demonstrate a clear association of cytokine and neuronotox- 
icity in cocultures of HIV-infected monocytes and astroglia. 
Arachidonic Acid Metabolites Induced during Cocultures of  HIV- 
infected Mono~tes and Astroglia: Implications for Cytokine Regu- 
lation and Neuronotoxicity.  Viable HIV-infected monocytes 
are required for the generation ofcytokines and neuronotox- 
icity. Supernatant fluids from astroglial ceils (U251 MG) mixed 
with  4%  par^formaldehyde-fixed  or  freeze-thawed  HIV- 
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Figure 4.  TNF-ot levels in culture fluids of HIV-infected monocytes 
cocultured with astroglia (U251 MG cells). Adherent monocytes cultured 
for 7 d were exposed to HIVe^ at a MOI of 0.01. At 7 d of infection 
HIV-infected and control uninfected monocytes were cocultured with equal 
numbers of astroglia. Aliquots of culture fluids were removed at various 
intervals and TNF levels measured by ELISA. 
infected monocytes or HIV-I^D^ viral stock (>10  s total par- 
ticles/ml) each failed to produce neuronotoxicity. These results 
suggested yet another component for both cytokine and neu- 
ronotoxic responses. For several reasons, arachidonic acid me- 
tabolites were pursued as this possible missing component. 
First, arachidonic acid metabolites are upregulated in mono- 
cytes after incubation with the viral envelope glycoprotein, 
gp120 (50).  Second, these metabolic products can regulate 
TNF-cz and IL-13 production in macrophages. Indeed, TNF 
causes amplification of arachidonic acid metabolites in response 
to IL-1, while PAF enhances TNF production (59-61).  An 
autocrine/paracrine loop between arachidonic acid metabo- 
lites and cytokines and vice versa could explain the need for 
viable cell-to-cell  interactions. Third, arachidonic acid me- 
tabolites play important roles in development neurobiology, 
neuronal  function,  and  were  reported  as  neuronotoxins 
(62-64).  For these reasons, we determined whether arachi- 
donate metabolites were produced during HIV-infected mono- 
cytes-astroglia  interactions and whether they played a phys- 
iologically important role in this experimental system. 
HPLC separation of arachidonic acid metabolic products 
released  from uninfected control monocytes, HIV-infected 
monocytes, uninfected monocytes and U251 MG astroglial 
cells, and HIV-infected monocytes and U251 MG astroglial 
cells were evaluated.  Cells were radiolabeled  with [3H]ara- 
chidonic acid for 18 h before coculture. The arachidonic me- 
tabolites were identified based on elution position standards 
(Table 4) and use of increasing polar solvents. The dution 
profiles of uninfected control (Fig. 8, broken lines) and HIV- 
1711  Genis et al. 
5000 
4000 
3000 
2000 
1000 
HIV-infected  monocytes  / 
_......d  control mono(:ytes 
f  + astrogl!a  ....... 
~...~,...,.~  .......  ~- 
0  5  10  15  20 
Hours  after  cocultivation 
i 
26 
Figure 5.  Ibl/$ levels  in culture fluids ofHIV-infected monocytes cocul- 
tured with astroglia (U251 MG cells). Adherent monocytes cultured for 
7 d were exposed to HIVxD^ at a MOI of 0.01. At 7 d of infection HIV- 
infected and control uninfected monocytes were cocultured  with equal 
numbers of astroglia. Aliquots of culture fluids were removed at various 
intervals and Ilrl/3 levels measured by ELISA. 
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Figure 6.  TNF activity in culture fluids ofHIV-infected monocytes  cocul- 
tured with astroglia (U251 MG cells). Adherent monocytes cultured for 
7 d were exposed to HIVAD^ at a MOI of 0.01. At 7 d of infection HIV- 
infected and control uninfected monocytes were cocultured  with equal 
numbers of astroglia. Aliquots of culture fluids were removed at various 
intervals, and TNF activity was measured by lysis of actinomycin D-treated 
L929 cells. Figure 7.  Induction  of  cytokine  mRNA in HIV-infected  monocyte  and 
U251 MG cells after treatment with cycloheximide  and actinomycin D. 
Monocytes  cultured 7 d as adherent monolayers  were exposed  to HIV at 
an MOI of 0.01. 7 d after infection HIV-infected  or control uninfected 
monocytes were treated with cycloheximide  (30 #g/ml) or actinomycin 
D (5/~g/ml) for 1 h. After 3 h IkNA was extracted from cell lysates  and 
then mixed with antisense primers. After RT, cDNAs were amplified  by 
PCR and the products of 25 cycles  analyzed  by Southern blot hybridiza- 
tion with  a TNF-c~-specific  probe (see Table I).  Coupled RT-PCR 
amplification products from cell lysates of uninfected and HIV-infected 
monocytes cocultured with U251 MG astroglial cells and treated with 
or without cycloheximide,  actinomycin  D, or media (control) are shown. 
infected monocytes (Fig.  8, solid lines) were virtually indis- 
tinguishable  (Fig.  8, b, d, andJ).  Based on elution times of 
standard  eicosanoids  (Table  4),  low levels  of LTB4, LTD4, 
and 15-HETE were detected at 90 s (Fig.  8 b) but were not 
sustained at 90 and 180 min (Fig. 8, d andj), However, HPLC 
analysis  of the  arachidonate  products  released  from  HIV- 
infected monocytes after coculture with U251 MG astroglial 
cells (Fig.  8, a, c, and e, solid line) revealed  signature profiles. 
Based on elution times of 3H standard (Table 4), the major 
products  of the  lipoxygenase  pathway  were LTB4, LTD4, 
and  lipoxin  A4  (Fig.  8,  a,  c,  and  e).  Although  increased 
amounts of 5-HETE methyl ester and lactone were in HIV- 
infected cells  the levels  of these metabolites were indistin- 
guishable between infected and uninfected (Fig.  8, a, c, and 
e, block broken lines) cell cocultures. Major increases were also 
seen in levels of 5-HETEs,  methyl ester,  and ~-lactone.  In- 
terestingly, LTB4 levels were transient,  produced at 90 s, but 
not  sustained.  This  is  in  keeping  with  its  known  cyclical 
production  (65).  Moreover,  cyclooxygenase products  were 
identified only at low levels.  Uninfected monocytes cocul- 
tured with astroglia produced 15-HETE, a metabolite found 
in low quantities in HIV-infected cells (Fig.  8, a, c, and e). 
The  differences in  the metabolic arachidonate  profiles per- 
sisted through 90 min. At that time HIV-infected monocyte- 
astroglia cocultures showed a >20-fold increase in LTD4 and 
uninfected cultures showed a >14-fold increase in 5-HPETE. 
LTB4 oxidation products were cyclic but were always greater 
in  HIV-infected  cocultures.  By  180  rain,  LTD,  levels  re- 
mained  elevated  in  HIV-infected  cocultures  and  increased 
greater than  fourfold from cocultures of uninfected mono- 
cytes and  astroglia. 
The levels of PAF were evaluated by a quantitative  klA. 
Increased levels of PAF in cocultures of HIV-infected mono- 
cytes  and  astroglia  were  strongly  associated with  TNF-ot 
Table  4.  Elution Time  of Selected Eicosanoids 
Metabolite  Time  Pathway 
rain 
6-kPGF1  6.0  Cyclooxygenase 
LTB4  oxidation  product  8.3  5-1ipoxygenase 
TXB2  11.2  Cyclooxygenase 
PGF2~  14.6  Cyclooxygenase 
PGE2  18.5  Cyclooxygenase 
Lipoxin  A4  21.8  5,  15-1ipoxygenase 
LTC4  23.5  5-1ipoxygenase 
LTE4  26.4  5-1ipoxygenase 
LTB4  30.1  5-1ipoxygenase 
LTD4  41.0  5-1ipoxygenase 
15-HETE  44.0  15-1ipoxygenase 
15-HPETE  49.1  15-1ipoxygenase 
12-HETE  52.1  12-1ipoxygenase 
5-HETE  56.5  5-1ipoxygenase 
5-HPETE  60.4  5-1ipoxygenase 
15-HEDE  65.0  Internal  standard 
15-HETE  methyl  ester  71.5  15-1ipoxygenase 
5-HETE methyl ester  75.9  5-1ipoxygenase 
5-HETE 5 lactone  79.5  5-1ipoxygenase 
Arachidonic  acid  83.0  - 
Eicosatrienoic acid  92.0  Internal  standard 
production  (Table  5).  To investigate  a possible casual rela- 
tionship between arachidonic acid metabolites and TNF-ot, 
we added dexamethasone,  an inhibitor  of phospholipase A; 
indomethacin, a cyclooxygenase  inhibitor; or NDGA, a lipox- 
ygenase inhibitor  (at concentration  used),  to cocultures of 
HIV-infected monocytes and astroglia, and measured TNF-a 
production  (Table 6).  Monolayers were infected with HIV 
at an MOI of 0.01  for 7 d before addition of U251 MG as- 
troglial cells. The compounds were added together with equal 
numbers  of  astroglia.  Both  dexamethasone  and  NDGA 
markedly reduced the levels of TNF-ot in supernatant  fluids 
of these cocultured cells. Interestingly,  indomethacin increased 
TNF-ot levels. This likely reflected shunting of the arachidonate 
metabolites  into  the  lipoxygenase pathway.  The  failure  of 
NDGA to completely abrogate the TNF-et response suggests 
that PAF also participates in this cytokine response.  Indeed, 
TNF-ot is reprodudbly detected after addition of PAF to cocul- 
tures  of uninfected monocytes and astroglia  (P.  Genis,  un- 
published observations). Thus,  arachidonic acid metabolites 
and  PAF both  likely  participate  in  the  TNF-ct  induction 
demonstrated  in  this  experimental  system. 
Discussion 
In the present study we demonstrated that the interactions 
between HIV-infected human monocytes and astroglia pro- 
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Figure 8.  Arachidonic acid elution profiles ofmonocytes after 
HIV infection and cocultivation of HIV-infected monocytes and 
U251 astroglial cells. Adherent monocytes cultured for 7 d were 
exposed to HIVAD^ at a MOI of 0.01. At 7 d of infection HIV- 
infected and control uninfected monocytes (5  ￿  106 cells) were 
incubated and cocultured with equal numbers of astroglia (U251 
MG cells). At various time intervals, 20 s to 180 rain, the genera- 
tion of arachidonic metabolites was examined. The metabolites 
were extracted, separated by HPLC, and analyzed quantitatively 
by determining DPM in the recovered fractions. The chromato- 
grams were adjusted based on recovery of internal standards (see 
Table  6) as described  in Materials and Methods. (a, c, and e) Cocul- 
tures of HIV-infected (solid lines)  or uninfected control (broken 
line) monocytes and astrogial (U251 MG cells). (b, d, andJ~ HIV- 
infected (solid lines) and uninf~ted control (broken line) monocytes. Table  5.  PAF Levels after HIV Infection and Coculture of 
HIV-infected Monocytes and Astroglia 
PAF levels at: 
Cell cultures  60 rain  120 min 
pg/lO 6 cells 
Monocytes  cultured  with: 
U251 MG astroglial  cells  260  100 
HIV-infected monocytes cultured with: 
Medium  360  100 
U251  MG astroglial  cells  990  670 
U251 MG astroglial  cells cultured 
with: 
Medium  130  200 
PAF production in cultured cells. Monocytes  cultured 7 d as adherent 
monolayers were exposed to HIV at a MOI of 0.01.1 wk after infection 
virus-infected  monocytes were cocultured  with equal numbers  of U251 
MG astroglial cells. At 60 and 120 min of coculture,  the cells were lysed 
and  PAF levels determined  by R.IA. 
duced high levels of IL-13 and TNF-ol. The Ib13 and TNF-ot 
responses were cytokine specific, correlated with neuronotox- 
icity,  and occurred only during coculture of HIV-infected 
monocytes and astroglia. TNF-/L Iblot, IL-6, and IFN-q/were 
not produced. Mixtures of neuronal or endothelial cells and 
HIV-infected monocytes failed  to  elicit  cytokines or neu- 
ronotoxins. Interestingly, the addition of TNF-ot and Ib13 
alone or in combination to neurons at the concentrations found 
in HIV-infected monocyte-astroglia culture fluids did not pro- 
duce neuronotoxicity. Viable glial cell-to-cell interactions were 
Table  6.  Effect of Arackidonic Acid Inkibitors on the TNF 
Levels after Coculture of HIV-infected Monocytes and Astroglia 
TNF-ot protein  at: 
Cell treatments  12 h  48 h 
pg/ml 
Medium  3,100  1,760 
Dexamethasone (10 -5 M)  50  30 
Indomethacin (0.4/~g/ml)  5,030  5,340 
Nordihydroguaiaretic acid (NDGA) 
(5  x  10 -s M)  602  550 
Effect of arachidonic acid inhibitors  on TNF production.  Monocytes cul- 
tured 7 d as adherent  monolayers  were exposed  to HIV at an MOI of 
0.01.1 wk after infection virus-infected monocytes were cocultured with 
equal numbers  of U251  MG astroglial  cells. At the time of coculture 
the cells were incubated  with medium,  dexamethasone  (10 -s M),  in- 
domethacin (0.4/~g/ml) or NDGA (5  x  10 -s M). TNF production  was 
measured by ELISA. Data represent  means of duplicate  determinations 
for one of three experiments  performed. 
required.  Moreover, HIV-infected monocyte culture fluids, 
sucrose gradient-concentrated viral partides, and paraformal- 
dehyde-fixed or freeze-thawed HIV-infected monocyte cell 
membranes failed to produce cytokine or neuronotoxic activity 
when placed on astrocytes. These data, taken together, sug- 
gested that other factor(s) were required for the observed re- 
sponses. Two of these factors were identified as lipidic com- 
pounds derived  from  membrane phospholipids,  including 
products of the 5-1ipoxygenase pathway and PAE These prod- 
ucts, potent low molecular weight mediators of immune ac- 
tivation, were secreted within 90 s of the mixture between 
HIV-infected monocytes and astroglia.  The large numbers 
of HIV-infected macrophages and astrogliosis in virus-infected 
brain tissue coupled with histological evidence of neuronotox- 
icity support the biological relevance of these observations. 
Pathological outcomes of HIV-1 infection in brain tissue 
include neuronal loss, reactive astrogliosis, and myelin damage 
(66).  Neuronal loss (67) is strongly associated with axonal 
and dendritic damage in the cortex and subcortex of affected 
individuals (68,  69).  The paucity of productively infected 
neurons supports indirect mechanisms for neuronal damage 
seen during HIV disease (6-10).  Indeed, viral antigens are 
found predominantly, if not exclusively, in cells  of macro- 
phage lineage (microglia, macrophages, and multinucleated 
giant cells). 
It is tempting to attribute  the pathogenesis of HIV en- 
cephalopathy  to  secretory  products  produced  from  HIV- 
infected macrophages or through the interactions between 
HIV-l-infected macrophages and astrocytes. Perhaps interplay, 
or "synergy" occurs between a number of toxic factors, in- 
cluding cytokines, arachidonic acid metabolites, and viral struc- 
tural and/or regulatory proteins (gp120, tat, nef, etc.). Our 
results support such a notion and suggest that cytokines, viral 
proteins, and lipidic compounds produced during glial cel- 
lular interactions all play roles in the neuropathogenesis of 
HIV disease.  Arachidonate metabolites and PAF may con- 
tribute to neuronal injury while stimulating TNF-ot and Ib13 
production, resulting in astroglial proliferation  (60,  61). 
Macrophages play a pivotal role in the generation of the 
described neuronotoxin response. This result is not surprising. 
Indeed, macrophages can contribute to disease progression 
by several mechanisms. At sites of infection macrophages se- 
crete scores of toxic effector molecules that damage tissue. 
Proliferation of autoreactive T  cells through indigenous an- 
tigen presentation also leads to tissue damage and occurs in 
multiple sclerosis and rheumatoid arthritis (70, 71). In mul- 
tiple sclerosis,  cytokines produced from macrophages and T 
cells produce myelin damage. In rheumatoid arthritis, the secre- 
tion of monokines leads to alterations in endothelial cell adhe- 
sion and neutrophil influx. Ultimately, alterations in macro- 
phage secretory and antigen-presenting functions leads to brain 
inflammation in multiple sclerosis and synovial hyperplasia 
of cartilage, tendons, and subchondral bone in rheumatoid 
arthritis. 
The absence of critical regulatory signals between macro- 
phages, microglia, and astrocytes may also contribute to the 
CNS disease process. Macrophages play important roles in 
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cytes regulate steady-state homeostatic CNS function. These 
functions provide an additional means for how HIV might 
disrupt neural function. For example, a critical homeostatic 
factor required for neuronal function might be lost because 
of HIV macrophage infection. However, the lack of supporting 
experimental evidence for this mechanism, the focality of tissue 
pathology and disease progression seen without large numbers 
of virus-infected cells, suggests  that  HIV-associated  neu- 
ropathology occurs through the daboration of toxic factors. 
The astrocyte functions, in this experimental system,  in 
a supportive role for cytokines and neuronotoxin induction. 
Although astrocytes can produce toxins (e.g.,  quinolinate) 
(72, 73) and secrete cytokines after appropriate stimulation, 
(e.g.,  IL-1, IL-3, TNF, and II.,6) (74),  there is no evidence 
that the astrocyte produces any such factors in vivo (75). 
Moreover, cycloheximide and actinomycin D added to HIV- 
infected  monocytes  significantly  reduced  or  diminated 
cytokines within culture fluids of HIV-infected monocytes 
and astroglia. Nonetheless, astrocytes are required for cytokine 
and neurotoxin production. This suggests that they play an 
important role in the generation of CNS injury during HIV 
encephalopathy. 
TNF and Ibl likely contribute to the in vivo neuropa- 
thology of HIV infection. TNF regulates class I and II MHC 
antigens and induces proliferation of astrocytes.  Addition- 
ally, TNF can cause myelin damage and lysis in oligodendro- 
cytes and upregulates HIV gene expression in monocytic cells 
(51-54, 76). During HIV infection in brain, increased levels 
of TNF and/or IL-1 can induce intracellular adhesion mole- 
cule 1 expression (77) in endothelial cells and/or astrocytes. 
Thus, TNF can facilitate  the production of inflammatory 
infiltrates  in brain parenchyma and permit the penetration 
of virus-infected monocytes through the blood-brain barrier. 
Several lines of evidence demonstrate that the regulation 
of TNF and II.-1 revolves around both the production of ara- 
chidonic acid metabolites and PAE First, the addition of dexa- 
methasone, a potent inhibitor of phospholipase A, to cocul- 
tures of HIV-infected monocytes and astroglia abrogates this 
cytokine response.  Second, downregulation in TNF-ce was 
seen with NDGA, an inhibitor of the lipoxygenase pathway, 
while indomethacin, a cyclooxygenase inhibitor, increased 
TNF-ot production. Third, a temporal relationship between 
production of LTB~, LTD4, lipoxin A4, and PAF and TNF 
was  shown. PAF enhances TNF production by inducing 
5-1ipoxygenase activity in macrophages (60,  61). PAF also 
causes the release of LTB4 suggesting an interrelationship be- 
tween the stimulation of TNF by PAF and endogenous lipox- 
ygenase activity (61). TNF and IL-1 can also induce LTB4 
in human macrophages. The addition of PAF alone or in 
combination with LTB4 into uninfected monocytes and as- 
troglia cocultures induced TNF activity (P. Genis, unpub- 
lished  observation).  Last,  the  HIV  glycoprotein (gp120) 
strongly upregulates (up to 40-fold) arachidonic acid metab- 
olites and 1L,1 activity in human monocytes (50). In this fashion 
HIV-1 gp120 may be inducing TNF-c~ and IblB in primary 
brain cultures (78). 
There is precedent for the ability of HIV-l-infected mono- 
cytes to trigger cytokine production from calls during cell- 
to-cell contact (e.g.,  IFN-ot from PBMC and TGF-~8 from 
astrocytes)  (30,  79).  PBMC cocultured with HIV-infected 
monocytes release high levels of IFN-a activity. Levels  of this 
IFN are associated with the interstitial pneumonitis seen in 
ungulate lentiviral infections and in children infected with 
HIV (80). The release of TGFo~, a potent chemotactic factor, 
is initiated from the interactions between HIV-infected mac- 
rophages and astrocytes. The production of TGF-~ in brain 
likely permits recruitment of HIV-infected monocytes into 
brain, providing a mechanism for efficient viral spread and 
disease (79). The exact secretory factors that regulate neural 
injury in HIV disease likely revolve around combinations of 
factors including arachidonic acid metabolites, cytokines, and 
other toxins.  Nonetheless, the mechanism of cytokine and 
neuronotoxic factor induction described in this report cou- 
pled with identifiable compounds that augment the neuro- 
logical response should prove helpful in understanding the 
basic mechanisms underlying HIV-induced CNS injury and 
for providing therapeutic strategies for AIDS-associated  en- 
cephalopathy. 
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